Aerocrine completes USD 50 million debt and equity financing
Aerocrine has completed a financing with the U.S. investment firm OrbiMed Advisors and with Novo A/S consisting of USD 35 million of debt and is also raising SEK 95 million (approximately USD 15 million) of equity from OrbiMed and a number of institutional investors through a directed share issue. The proceeds will be utilized to continue funding growth and expanded commercialization of its current product as well as its pipeline of new devices for diagnosis and management of airway inflammation.
Aerocrine is a medical technology company focused on improving the treatment of patients with inflamed airways such as asthma. The company has its headquarters in Solna, Sweden and its share is listed on NASDAQ OMX Stockholm.
Aerocrine has been advised by Mannheimer Swartling on legal matters in the financing. The firm’s team was led by Thomas Pettersson, Eva Hägg and Nils Nostell, and included Claudia Wallman, Veronica Stiller, Therese Jansson, Dijana Malicbegovic and David Nordenlöw.